Zobrazeno 1 - 10
of 74
pro vyhledávání: ''
Publikováno v:
International Journal of Gynecologic Cancer. 31:824-828
ObjectiveIn this study we investigated response rates of bevacizumab in addition to weekly paclitaxel and carboplatin in neoadjuvant setting in cervical cancer stage IB–IIB.MethodsIn this retrospective study we included patients with FIGO 2018 stag
Autor:
Hee Seung Kim, Hyunhoon Chung, Se Ik Kim, Eun Ji Lee, Maria Lee, Jae Weon Kim, Yong Sang Song, Noh Hyun Park
Publikováno v:
International Journal of Gynecologic Cancer. 30:1943-1950
ObjectiveEvidence on recurrence patterns after bevacizumab in epithelial ovarian cancer is still insufficient. The aim of this study was to evaluate recurrence patterns after treatment with bevacizumab as second-line treatment in patients with platin
Autor:
Anca Chelariu-Raicu, John J. Kavanagh, Brian M. Slomovitz, Robert L. Coleman, Christopher Morrison, Diane C. Bodurka, Judith K. Wolf, David M. Gershenson, Charles F Levenback
Publikováno v:
International Journal of Gynecologic Cancer. 30:1768-1774
Introduction50–70% of epithelial ovarian cancers overexpress epidermal growth factor receptor, and its expression has been correlated with poor prognosis. We conducted a phase Ib/II trial to examine the efficacy, safety, and toxicity of gefitinib,
Autor:
Elise B. Morocco, Begüm Özel, Koji Matsuo, Christina E. Dancz, Marcia A. Ciccone, Mahdi Khoshchehreh, Lynda D. Roman, Heena Pursuwani, Rachel S. Mandelbaum, Richard J. Paulson, Shinya Matsuzaki
Publikováno v:
International Journal of Gynecologic Cancer. 30:1-9
IntroductionPrevious studies have suggested that metformin use may enhance the therapeutic effect of progestin therapy for endometrial hyperplasia or malignancy. However, it is not known how the impact of concurrent metformin may be altered by route
Autor:
Yeon Joo Kim, Ha Kyun Chang, Sang Hee Youn, Myong Cheol Lim, Sang Yoon Park, Sang Soo Seo, Sokbom Kang, Joo-Young Kim
Publikováno v:
International Journal of Gynecologic Cancer. 30:764-771
ObjectiveThe aim of this study was to compare the clinical outcomes of chemoradiotherapy with or without bevacizumab in patients with newly diagnosed International Federation of Gynecology and Obstetrics (FIGO) stage IVB cervical cancer.Methods41 pat
Autor:
Clare Green, Gianfilippo Bertelli, Marcia Hall, Chit Cheng Yeoh, Steve Chan, Timothy J. Perren, Louise Li, Agnes Ograbek, Rachel Jones, Jurjees Hasan
Publikováno v:
International Journal of Gynecologic Cancer. 30:213-220
ObjectiveTwo randomized phase III trials demonstrated the efficacy and safety of combining bevacizumab with front-line carboplatin/paclitaxel for advanced ovarian cancer. The OSCAR (NCT01863693) study assessed the impact of front-line bevacizumab-con
Publikováno v:
International Journal of Gynecologic Cancer. 29:1411-1416
ObjectivesPre-operative opioid use is common and should be considered a comorbidity among surgical candidates. Our objective was to describe the rate of pre-operative opioid use and patterns of post-operative outpatient opioid prescribing in a cohort
Autor:
Josephine S. Kim, Kristine R. Penner, Chi E Wang, Rebecca A. Brooks, Jean A. Hurteau, Margaret I. Liang, Jill Alldredge, Tilley Jenkins Vogel, Carolyn V. Kirschner, Joshua G. Cohen, Avisek Datta, Ilana Cass, Gustavo C. Rodriguez, E.N. Prendergast, E.D. Moore
Publikováno v:
Int J Gynecol Cancer
ObjectivesTo compare clinical outcomes for stage IIIC and IV ovarian cancer patients receiving neoadjuvant chemotherapy and interval cytoreductive surgery followed by up to three versus more cycles of post-operative chemotherapy.MethodsWe conducted a
Autor:
Ana de Juan Ferré, Isabel Bover Barcelo, Margarita Romeo Marin, M. Gil-Martin, Aránzazu Manzano, Y. García, Lydia Gaba Garcia, Cristina Arqueros Núñez, Maria-Pilar Barretina-Ginesta, Elena García-Martínez, Antonio Gonzalez Martin, Cesar Mendiola, Maria Jesús Rubio Pérez, Ana Santaballa Bertrán
Publikováno v:
International Journal of Gynecologic Cancer. 29:1050-1056
BackgroundBevacizumab is an approved treatment after primary debulking surgery for ovarian cancer. However, there is limited information on bevacizumab added to neoadjuvant chemotherapy before interval debulking surgery.ObjectiveTo evaluate neoadjuva
Role of salvage therapy in chemo resistant or recurrent high-risk gestational trophoblastic neoplasm
Autor:
Vijay C R, Arpitha Anantharaju, K Shobha, U. D. Bafna, Rajshekar Kundargi, V R Pallavi, Praveen S. Rathod
Publikováno v:
International Journal of Gynecologic Cancer. 29:547-553
ObjectivesTo assess the importance of salvage therapy in the management of high-risk gestational trophoblastic neoplasia (HR GTN) after failure of first line multiagent chemotherapy.MethodsThis retrospective study involving women with HR GTN treated